Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 29;32(5):460–467. doi: 10.1093/ajh/hpz009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 1. — Blood pressure, renal collagen synthesis and morphology in rats received aldosterone (ALDO) with/without angiotensin 1–7 (Ang1-7) co-treatment. ALDO infusion significantly elevated blood pressure in rats, which was not affected by Ang1-7 co-treatment (a). Type 1 collagen (Col-1) mRNA (b) and CVF (c) in the kidney were significantly increased in ALDO-treated rats, which was significantly suppressed by Ang1-7. Compared to the control kidney (d and g), glomerular damage/necrosis (arrow, e) and sclerosis (h) appeared in ALDO-treated rats. Ang1-7 co-treatment improved glomerular injury () and fibrosis (i). Panels a–c: ^*P < 0.05 compared to control group (CTL); ^#P < 0.05 compared to ALDO group (n = 6/group); Panels d–f: ×400.